AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00867490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren+HCTZ - Phase 2
Description: Patients with uncontrolled mean sitting diastolic blood pressure (msDBP ≥ 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.
Study NCT00867490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren+HCTZ+amlodipine - Phase 3
Description: The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP ≥ 90 mm Hg and/or msSBP ≥ 140 mm Hg) at the end of Phase 2 were offered 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg in a single tablet plus an amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.
Study NCT01154608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon
Study NCT01154608 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No enzyme therapy
Description: Current enzyme therapy of the patient is stopped during 7 days
Study NCT04285060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung GEMS-H
Description: Subjects will participate in 18 sessions of training in the outpatient clinic with a licensed physical therapist. Therapy sessions will include 30 minutes of task specific training and another 15 minutes of the session can be used to focus on patient specific goal areas related to functional mobility and balance. Training sessions will occur 2-3 times a week for 6-8 weeks to complete the training protocol.
Study NCT01739426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repair w/LigaSure
Description: Surgical repair is carried out as normal except that a novel device is used: LigaSure V (TM) laparoscopic instrument (reference LS1500)
Study NCT01759927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity coaching
Description: After measuring physical actity, physical fitness level, anthropometric and psychosocial variables a personalized 12 week physical activity program is made (=baseline). The intervention consisted of two face-to-face counselling sessions at the start of the intervention, short contacts by e-mail or telephone at weeks 3, 6 and 9, and two face-to-face counselling sessions at the end of the intervention. Employees exercise on their own. After 12 weeks and 6 months all measures are repeated.
Study NCT02505256 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00332904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
Study NCT00332904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
Study NCT02945657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM36 topical ointment, 1%
Description: Twice daily application for 28 consecutive days
Study NCT00502840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1g iv on days 1 and 15
Study NCT03240926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Loop Band
Description: Application of Loop band on radial artery of the opposite wrist that the Anesthesiologist has placed the Arterial line.
Study NCT03375385 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dexmedetomidine/ propofol
Description: The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).
Study NCT03488199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent Acculink ™
Description: Carotid Artery Revascularization using Stents
Study NCT03488199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGuardTM™
Description: Carotid Artery Revascularization using Stents
Study NCT02937805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moisturizing vaginal and vulvar sea buckthorn oil cream
Study NCT02937805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizing vaginal and vulvar cream
Study NCT01591005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sonolysis
Description: continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes
Study NCT01591005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endarterectomy
Description: carotid endarterectomy
Study NCT01591005 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: endarterectomy
Description: carotid endarterectomy
Study NCT01591005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carotid stenting
Description: percutaneous transluminal angioplasty and stenting
Study NCT01591005 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: carotid stenting
Description: percutaneous transluminal angioplasty and stenting
Study NCT00833092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill supplementation for 9 weeks
Study NCT00833092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: magnesium
Description: 300 milligrams daily for 8 weeks
Study NCT03700047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAL1704
Description: new dermal filler
Study NCT03700047 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm Voluma
Description: hyaluronic acid
Study NCT01621932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct anterior approach with capsulectomy
Description: Direct anterior approach with capsulectomy
Study NCT01621932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct anterior approach without capsulectomy
Description: Direct anterior approach without capsulectomy
Study NCT03417440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical Activity (PA) Tracker App
Description: This PA tracker app auto-monitors PA and provides a text-based summary of goal progress, thereby targeting self-regulation and outcome expectation.
Study NCT03417440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: On Your Feet
Description: On Your Feet is a specialty app feature designed to be paired with a PA tracker app and reduce sedentary activity-a health risk factor largely independent of insufficient PA. This feature utilizes self-regulatory and behavior change techniques including goal-setting, progress feedback, and prompting. Accumulated sedentary activity time is displayed alongside self-selected goals; reminders to stand are sent at a user-specified frequency; and general tips and previously compiled, older adult-identified strategies to reduce sedentary activity are texted. Additionally, messages about the benefits of reducing sedentary activity and overcoming barriers are sent.
Study NCT03417440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Coach Me
Description: Coach Me is a specialty app feature designed to be paired with a PA tracker app and includes daily messages that assist older adults in discovering practical ways to integrate PA into their daily routines and overcoming PA barriers. Blending PA with productive activity facilitates PA engagement in older adults. In Coach Me, suggestions on how to intensify daily activities are tailored based on user selections from an activity inventory. This app feature helps older adults become more active in a minimally intrusive way, while allowing for engagement in productive and meaningful activities. Coach Me asks users to select obstacles to PA encountered in the previous week. Based on those selections, the app sends strategies on how to overcome those barriers, thereby targeting self-efficacy.
Study NCT03417440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Proof Positive
Description: Proof Positive is a specialty app feature designed to be paired with a PA tracker app and capitalizes on the beneficial effects that exposure to positive aging messages and stereotypes has on health and PA. When activated, users (a) receive texts describing how old age does not equate to physical inability, (b) obtain information about the benefits of growing older, and (c) are presented with a weekly positive aging stereotype task modeled after a computerized series. This last function exposes users to blocks of positive priming words. Primers are quickly flashed to allow perception without awareness while users focus on a simple icon that represents PA. Icons are intended to provide an additional PA cue, maintain user interest, and increase the external validity.
Study NCT02586805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930 - 300mg/2wk
Description: 300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
Study NCT02586805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930 - 300mg/4wk
Description: 300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
Study NCT02586805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930 - 150mg/4wk
Description: 150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
Study NCT02586805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered every 2 weeks by subcutaneous injection.
Study NCT03182764 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00087438 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Study NCT02086227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon for Injection (Fresenius Kabi USA)
Description: Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)
Study NCT02086227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon for Injection (Bedford Laboratories)
Description: Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)
Study NCT01843010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib
Description: Parecoxib 40mg will be intravenously infused.
Study NCT01843010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 5ml will be intravenously infused.
Study NCT02906553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceryl Trinitrate
Study NCT02906553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03314506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will exercise on a treadmill for 1 hour at a moderate intensity (approximately 70% of their predicted VO2peak).
Study NCT02734173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT450r-ABT267-ABT333 +/- Ribavirin
Description: 12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin
Study NCT03744455 — intervention group
Intervention type: BIOLOGICAL
Intervention: Axillary Plexus
Description: Axillary plexus anesthesia technique for hand surgery
Study NCT00316264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab, palivizumab
Description: Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
Study NCT00316264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palivizumab, motavizumab
Description: Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
Study NCT00316264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
Study NCT02494570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Sirolimus
Description: Patients received nab-sirolimus at 100 mg/m2 on Days 1 and 8 of a 21-day cycle by intravenous infusion over 30 minutes.
Study NCT02036320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
Study NCT02036320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
Study NCT04203914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin Tablets
Description: Add-on 25mg once daily
Study NCT01625806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO4602522
Description: Single oral dose
Study NCT01625806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Single oral dose
Study NCT01625806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: Multiple oral doses
Study NCT02814773 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Study NCT04824716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postconditioning
Description: The protocol of primary PCI followed by stenting is executed according to the descriptions according to the majority of relevant scientific literature on postconditioning studies and in accordance with the most recent guidelines. In the post conditioned group, after recanalization, the artery is occluded by inflation of stent balloon (4 times for 1-1 minute) followed by 1-1-minute reperfusion, repeatedly. Eight minutes after the start of examination, angiography is made in order to determine blood flow. Intervention is finished by the operator and another angiographic image is made (identical to initial standard projection).
Study NCT04824716 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention as per European Society of Cardiology guidelines.
Study NCT01986777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisdexamfetamine
Study NCT01986777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will be filled with lactose.
Study NCT03389685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Pure PRPII®, leukocyte-poor, platelet rich plasma
Study NCT03389685 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: saline solution
Study NCT03246425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator mode change
Description: The enrolled subjects will be moved from the baseline mode to another mode of ventilation and the changes in the arterial pulse will be observed
Study NCT01864356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT100
Study NCT01864356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00674154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: 2800 IE daily in 52 weeks
Study NCT00674154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 2800 IE daily in 52 weeks
Study NCT04650061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview (MI) & Adherence Follow-Up
Description: With MI, the key goal is to empower the patient to commit to follow CPAP therapy, while providing empathic support, in a positive atmosphere, and without prejudice. The nurse does not directly advocate for behavior change (i.e. use CPAP as prescribed), but asks key questions to help the patient explore their feelings about the change, weighs the pros and cons of such change, and allows the patient to realize the discrepancy between the current risk (that is, not using CPAP as directed) and the benefits with good adherence.
Study NCT04650061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adherence Follow-Up
Description: The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
Study NCT01716871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neurocryostimulation with Duo-cryo® device
Description: organized in the morning and in the evening during 3days. The gaz is sprayed with Duo-cryo® device on dry skin over the ankle using a slow, regular, sweeping movement. The tip of the nozzle is kept 15 to 20 cm away from the skin. Neurocryostimulation is applied to patients for a duration of one minute by a trained staff
Study NCT01716871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy with Cold pack® or ice-cubes pack
Description: Patients receive 2 controlled applications a day (one in the morning and one in the evening) of cryotherapy with Cold pack® or ice-cubes pack (with average dimensions of 5 cm by 8 cm) to the injury site for a duration of 20 minutes. Furthermore, the patients are instructed to do 2 more applications of the ice-pack during the daytime to follow the usual recommendations.~The first and last sessions of each day must be supervised by the medical care Unit to insure standardized data collection for each group.
Study NCT03553030 — intervention group
Intervention type: DEVICE
Intervention: coronary artery angiography
Description: In all patients authors performed a coronary artery angiography for detection of coronary artery stenosis.
Study NCT01278654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentive to exercise
Description: Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
Study NCT03246425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of blood pressure variation
Description: The changes in the blood pressure will be measured in the form of Stroke Volume Variation using SVV using Vigileo (Edward Life sciences) monitor
Study NCT04490889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NiPGT-A
Description: NiPGT-A is the technique to screen the aneuploidy status of an embryo without invasion technique, such as biopsy. We use SCM to isolate cfDNA, then amplify and analyse the aneuploidy of embryo secreting this material using NGS technique.
Study NCT00673595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.~The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day.
Study NCT00673595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
Study NCT03102190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Hydrochloride Intranasal
Description: Verapamil solution for injection, supplied in vials, will be utilized in a Neil Med Sinus Rinse of 240mL buffered normal saline.
Study NCT02985931 — intervention group
Intervention type: OTHER
Intervention: Diagnostic imaging scans of SPECT and MRI
Study NCT01609478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
Study NCT01609478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo delivered via Concept 1 inhaler
Study NCT01609478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: via Twisthaler inhaler
Study NCT01609478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mometasone furoate
Description: via Twisthaler inhaler
Study NCT00643240 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 anti-CD19 monoclonal antibody BU12
Description: Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
Study NCT00643240 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 111In-BU-12
Description: Patients receive indium-111 BU-12 IV over 60 minutes on day 0
Study NCT04919915 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HEPA air cleaner
Description: Participants in the intervention group received two HEPA air cleaners per household. They were informed to place the HEPA air cleaners in the child's bedroom and the living room. Field staff provided and discuss how to use the air cleaner which promoted continuous operation of both air cleaners, keeping the child's bedroom door closed, and selected the highest fan speed. Typical use of the HEPA cleaners were questioned during the mid-study and final visits.